Biological determinants of intestinotrophic properties of GLP-2 in vivo

Anne Tsai, Mary Hill, Daniel J. Drucker

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Glucagon-like peptide 2 (GLP-2) appears to regulate growth of the small bowel epithelium. The importance of dose, vehicle, and route of administration for GLP-2 bioactivity was examined in vivo. Mouse small bowel weight increased following subcutaneous injection of GLP-2, 0.25 to 5.0 μg twice daily, with an increment in jejunal crypt plus villus height detected with only 250 ng GLP-2 twice daily for 14 days (1.35-fold greater than control, P <0.05). Small bowel weight was increased by 6 days of GLP-2 administration (1.4-fold greater than control, P <0.05) and further increased after up to 14 days of GLP-2 treatment (P <0.001, GLP-2 vs. control). GLP-2 increased small bowel weight in either 12% gelatin or phosphate-buffered saline (PBS) formulations (P <0.01 vs. P <0.05, gelatin vs. PBS, respectively), and GLP-2 was intestinotrophic following either intramuscular, intraperitoneal, or subcutaneous administration (P <0.05 for im and ip, P <0.001 for sc, GLP-2 vs. control). GLP-2 also induced bowel growth when administered daily or every other day. These results define important biological parameters for the activity of GLP-2 in vivo.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume272
Issue number3 35-3
StatePublished - Mar 1997
Externally publishedYes

Fingerprint

Glucagon-Like Peptide 2
Gelatin
Weights and Measures
Phosphates
Subcutaneous Injections
Growth

Keywords

  • glucagon-like peptides
  • growth factor
  • intestine
  • mouse
  • small bowel

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology
  • Physiology (medical)

Cite this

Biological determinants of intestinotrophic properties of GLP-2 in vivo. / Tsai, Anne; Hill, Mary; Drucker, Daniel J.

In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 272, No. 3 35-3, 03.1997.

Research output: Contribution to journalArticle

@article{03487037892b4fdd96c710201ca038b5,
title = "Biological determinants of intestinotrophic properties of GLP-2 in vivo",
abstract = "Glucagon-like peptide 2 (GLP-2) appears to regulate growth of the small bowel epithelium. The importance of dose, vehicle, and route of administration for GLP-2 bioactivity was examined in vivo. Mouse small bowel weight increased following subcutaneous injection of GLP-2, 0.25 to 5.0 μg twice daily, with an increment in jejunal crypt plus villus height detected with only 250 ng GLP-2 twice daily for 14 days (1.35-fold greater than control, P <0.05). Small bowel weight was increased by 6 days of GLP-2 administration (1.4-fold greater than control, P <0.05) and further increased after up to 14 days of GLP-2 treatment (P <0.001, GLP-2 vs. control). GLP-2 increased small bowel weight in either 12{\%} gelatin or phosphate-buffered saline (PBS) formulations (P <0.01 vs. P <0.05, gelatin vs. PBS, respectively), and GLP-2 was intestinotrophic following either intramuscular, intraperitoneal, or subcutaneous administration (P <0.05 for im and ip, P <0.001 for sc, GLP-2 vs. control). GLP-2 also induced bowel growth when administered daily or every other day. These results define important biological parameters for the activity of GLP-2 in vivo.",
keywords = "glucagon-like peptides, growth factor, intestine, mouse, small bowel",
author = "Anne Tsai and Mary Hill and Drucker, {Daniel J.}",
year = "1997",
month = "3",
language = "English (US)",
volume = "272",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "3 35-3",

}

TY - JOUR

T1 - Biological determinants of intestinotrophic properties of GLP-2 in vivo

AU - Tsai, Anne

AU - Hill, Mary

AU - Drucker, Daniel J.

PY - 1997/3

Y1 - 1997/3

N2 - Glucagon-like peptide 2 (GLP-2) appears to regulate growth of the small bowel epithelium. The importance of dose, vehicle, and route of administration for GLP-2 bioactivity was examined in vivo. Mouse small bowel weight increased following subcutaneous injection of GLP-2, 0.25 to 5.0 μg twice daily, with an increment in jejunal crypt plus villus height detected with only 250 ng GLP-2 twice daily for 14 days (1.35-fold greater than control, P <0.05). Small bowel weight was increased by 6 days of GLP-2 administration (1.4-fold greater than control, P <0.05) and further increased after up to 14 days of GLP-2 treatment (P <0.001, GLP-2 vs. control). GLP-2 increased small bowel weight in either 12% gelatin or phosphate-buffered saline (PBS) formulations (P <0.01 vs. P <0.05, gelatin vs. PBS, respectively), and GLP-2 was intestinotrophic following either intramuscular, intraperitoneal, or subcutaneous administration (P <0.05 for im and ip, P <0.001 for sc, GLP-2 vs. control). GLP-2 also induced bowel growth when administered daily or every other day. These results define important biological parameters for the activity of GLP-2 in vivo.

AB - Glucagon-like peptide 2 (GLP-2) appears to regulate growth of the small bowel epithelium. The importance of dose, vehicle, and route of administration for GLP-2 bioactivity was examined in vivo. Mouse small bowel weight increased following subcutaneous injection of GLP-2, 0.25 to 5.0 μg twice daily, with an increment in jejunal crypt plus villus height detected with only 250 ng GLP-2 twice daily for 14 days (1.35-fold greater than control, P <0.05). Small bowel weight was increased by 6 days of GLP-2 administration (1.4-fold greater than control, P <0.05) and further increased after up to 14 days of GLP-2 treatment (P <0.001, GLP-2 vs. control). GLP-2 increased small bowel weight in either 12% gelatin or phosphate-buffered saline (PBS) formulations (P <0.01 vs. P <0.05, gelatin vs. PBS, respectively), and GLP-2 was intestinotrophic following either intramuscular, intraperitoneal, or subcutaneous administration (P <0.05 for im and ip, P <0.001 for sc, GLP-2 vs. control). GLP-2 also induced bowel growth when administered daily or every other day. These results define important biological parameters for the activity of GLP-2 in vivo.

KW - glucagon-like peptides

KW - growth factor

KW - intestine

KW - mouse

KW - small bowel

UR - http://www.scopus.com/inward/record.url?scp=0030977884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030977884&partnerID=8YFLogxK

M3 - Article

C2 - 9124589

AN - SCOPUS:0030977884

VL - 272

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 3 35-3

ER -